PlainPharmaWatch

CMS Open Payments · Program Year 2024

Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc. reported $177,062.12 across General Payments, Research, and Ownership to 1,496 physicians and teaching hospitals across 1,496 transactions.

See the rankings → How this is sourced
$177.1K Below-median payer
All-tracks total
1,496 Top quartile volume
Transactions
1,496 Top quartile reach
Recipients
−$194.7K
General Payments vs PY2023

Eagle Pharmaceuticals, Inc. reported $177,062.12 across all CMS Open Payments tracks (General + Research + Ownership) to 1,496 physicians and teaching hospitals in Program Year 2024 - ranking #1039 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $177,062.12, averaging $118.36 per recipient.

How Eagle Pharmaceuticals, Inc.'s $177.1K all-tracks total breaks down

Eagle Pharmaceuticals, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

26/100

Total payments

F

12/100

Transaction volume

F

21/100

Physician reach

F

21/100

Payment type diversity

D

50/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer eagle-pharmaceuticals-inc Eagle Pharmaceuticals, Inc.

$177.1K · #1039/1,925 · 0.0% industry · PY2024

  • TOT $177.1K
  • RANK #1039
  • SHARE 0.0%
  • TXN 1,496
  • RCP 1,496
  • CAT 4
  • GEN $177.1K
  • ΔGEN −$194.7K
  • TOP1 16.7%
  • PY 2024

Volume peers

Nearest volume peer: Foundation Fusion Solutions, LLC ($177.0K)

Eagle Pharmaceuticals, Inc. …$177.1KFoundation Fusion Solutions,…$177.0KOptellum Ltd$176.8KDmg America LLC$176.1KCarestream Dental, LLC$175.9K
All-tracks payment totals near Eagle Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Eagle Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Eagle Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $194.7K (−52.4%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: EAGLE PHARMACEUTICALS, INC.PY2023: EAGLE PHARMACEUTICALS, INC.PY2024: EAGLE PHARMACEUTICALS, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$371.8KPY2024$177.1K
PY2023
$371,762.43
PY2024
$177,062.12

What the Data Shows for Eagle Pharmaceuticals, Inc.

The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Eagle Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.

Of the 4 general-payment categories charted below, "Honoraria" is the largest at $89.3K across 28 transactions, 50.4% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 4 types of general payments, Eagle Pharmaceuticals, Inc.'s largest category was "Honoraria" at $89.3K - 50.4% of General Payments.

Eagle Pharmaceuticals, Inc. reports 4 general-payment categories - the top three are Honoraria (50.4%), Food and Beverage (36.3%), and Travel and Lodging (13.1%). The remaining 1 category make up 0.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Eagle Pharmaceuticals, Inc. divides its payments

Ranked by total dollars reported per category

1. Honoraria$89.3K2. Food and Beverage$64.3K3. Travel and Lodging$23.1K4. Consulting Fee$375.00
Payment Type Amount Transactions
Honoraria $89.3K 28
Food and Beverage $64.3K 1,397
Travel and Lodging $23.1K 70
Consulting Fee $375.00 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $84,055.24 (47.5%) of $177,062.12 in this company's General Payments records across 1,229 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Eagle Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Randall D Ostroff$29.6KKevin Scott Henson$26.3KRonak G Desai$12.6KErik Scott Rauch$8.3KDavid G Leiman$7.2K
  1. 1

    Randall D Ostroff

    $29,608.83 across 40 reported transactions

  2. 2

    Kevin Scott Henson

    $26,275.66 across 46 reported transactions

  3. 3

    Ronak G Desai

    $12,633.76 across 16 reported transactions

  4. 4

    Erik Scott Rauch

    $8,304.63 across 16 reported transactions

  5. 5

    David G Leiman

    $7,232.36 across 4 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Eagle Pharmaceuticals, Inc.'s spend rank (#1039 of 1,925, bottom 46% by spend) and concentration rank (#1,204 of 1,838, bottom 35% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.

01.12.13.24.2636.4639.9643.5647.1650.6Total payments ($M)Concentration (HHI, 0-10,000)
Eagle Pharmaceuticals, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Eagle Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Eagle Pharmaceuticals, Inc..

EyePoint Pharmaceuticals US, Inc.

HHI 640

Bone Support Inc.

HHI 641

Jenavalve Technology, Inc.

HHI 640

PENTAX of America, Inc.

HHI 642

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Eagle Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Eagle Pharmaceuticals, Inc. ranks #1039 of 1,925 by all-tracks total payments, led by "Honoraria".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Eagle Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.